Get started
Author

Karen Barrett

Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515).
2023 · Clifford Grant Robinson, Ligang Xing, et al. · Journal of Clinical Oncology · 18
PDF
PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
2025 · D. Planchard, P.A. Jänne, et al. · Journal of Thoracic Oncology · 11
630MO First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort
2024 · J.C-H. Yang, K. Kobayashi, et al. · Annals of Oncology · 5
PDF
122TiP Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515)
2022 · C. Robinson, L. Xing, et al. · Annals of Oncology · 5
Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).
2025 · Benjamin Philip Levy, Filippo de Marinis, et al. · Journal of Clinical Oncology · 4
Abstract CT080: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) in 1L metastatic NSCLC: Outcomes by blood tumor mutational burden (bTMB) in POSEIDON
2023 · Solange Peters, Hisani Madison, et al. · Cancer Research · 2
12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study
2023 · N. Reinmuth, B.C. Cho, et al. · Journal of Thoracic Oncology · 1
PDF
PS3-1 Overall survival with first-line osimertinib ± platinum-pemetrexed for EGFR-mutated advanced NSCLC: FLAURA2 Japan cohort
2026 · N. Yanagitani, P. Jänne, et al. · Annals of Oncology
PT2.03.03: Long-Term Safety Outcomes With Osimertinib Plus Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2
2026 · C.K. Lee, P.A. Jänne, et al. · Journal of Thoracic Oncology
27P Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum–pemetrexed (plat–pem) due to progression (PD): FLAURA2 exploratory analysis
2026 · C. Escriu, P.A. Jänne, et al. · ESMO Open
PDF
P3.12.65 First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype
2025 · S. Ahmed, J.C.-H. Yang, et al. · Journal of Thoracic Oncology
P3.12.62 First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort
2025 · P. Janne, M. Albayaty, et al. · Journal of Thoracic Oncology
Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
2022 · Byoung Chul Cho, Niels Reinmuth, et al. · Journal of Clinical Oncology
Works count: 13
Citation count: 46
H-index: 4
I10-index: 2
Year
Topic
Type